0
0
Market decides it’s good enough
The headline from the JNJ vaccine trial was 66% effectiveness and only 57% in South Africa, which has a worrisome variant.
On the surface, that doesn’t sound like the #1 vaccine that anyone wants to get but medical experts — including Fauci — have chimed in to say the news is better
Search Web: Market reconsiders Johnson & Johnson vaccine news
Recent Posts
- Crude Oil Over Crypto
- US Dollar Price Action Setups pre-CPI: EUR/USD, GBP/USD, USD/JPY
- Cathie Wood & Ark: Insiders Aren’t Buying the Hype
- Breaking News: ECB Holds Rates, Setting up July and September for Fireworks
- Currency Carry Trade: What is it and how does it work?
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
